Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIJQ0S634)
  Drug Name Methyldopa Drug Info Riociguat Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Vasodilator Agents
  Structure

 Mechanism of Methyldopa-Riociguat Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Methyldopa Riociguat
      Mechanism Antihypertensive agent
Alpha-2 adrenergic receptor  Agonist 		Hypotensive effects
Soluble guanylyl cyclase  Agonist
      Key Mechanism Factor 1
Factor Name Adrenergic receptor alpha-2 Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol.
    Click to Show/Hide
      Key Mechanism Factor 2
Factor Name Guanylate cyclase soluble Structure Sequence
Protein Family Adenylyl cyclase class-4/guanylyl cyclase family
Protein Function
Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Methyldopa and Riociguat 

Recommended Action
      Management Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.

References
1 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.